Maintenance Study News Today

On consolidated basis, company posted PAT of ₹ 15,417 crore and total income of ₹ 46,606 crore for FY23 registering a YoY growth of 11% and 9% respectively.

Investegate announcements from Fingrid Oyj, FINGRID GROUP – MANAGEMENT’S REVIEW 1.1.−31.3.2023

Kennedy Krieger Institute was ordered to pay a woman who said she was harmed in a 1990s study of lead paint remedies.

Fingrid Oyj: Fingrid Groups Financial Statements Bulletin January-December 2020: the weather significantly affected the formation of the result Stock exchange release 5 March 2021 at 12:00 noon EET Fingrids consolidated financial statements have been drawn up in accordance with the International Financial Reporting Standards (IFRS). Unless otherwise indicated, the figures in parentheses refer to the same period of the previous year. The information published in this report is based on Fingrids...

  * The Board of Directors’ proposal to the Annual General Meeting on the maximum dividend to be distributed Jukka Ruusunen, President & CEO of Fingrid: “Best-ever transmission reliability rate – the exceptionally warm year affected the result” In terms of capital expenditure, 2020 was a record-breaking year for Fingrid: we built transmission lines and substations at dozens of worksites. Even during the coronavirus pandemic, the capex projects progressed as planned. As a company ...

Published: Feb 22, 2021 AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences Inc., (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for simufilam, its lead drug candidate for the treatment of Alzheimer’s disease. Official EOP2 meeting minutes indicate FDA and Cassava Sciences agree on key elements of a p...